428 related articles for article (PubMed ID: 28379189)
1. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects.
Nguyen L; Papenhausen P; Shao H
Genes (Basel); 2017 Apr; 8(4):. PubMed ID: 28379189
[TBL] [Abstract][Full Text] [Related]
2. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
[TBL] [Abstract][Full Text] [Related]
3. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas.
Chisholm KM; Bangs CD; Bacchi CE; Molina-Kirsch H; Cherry A; Natkunam Y
Am J Surg Pathol; 2015 Mar; 39(3):294-303. PubMed ID: 25581730
[TBL] [Abstract][Full Text] [Related]
4. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
5. MYC and aggressive B-cell lymphomas.
Slack GW; Gascoyne RD
Adv Anat Pathol; 2011 May; 18(3):219-28. PubMed ID: 21490439
[TBL] [Abstract][Full Text] [Related]
6. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.
Sewastianik T; Prochorec-Sobieszek M; Chapuy B; Juszczyński P
Biochim Biophys Acta; 2014 Dec; 1846(2):457-67. PubMed ID: 25199984
[TBL] [Abstract][Full Text] [Related]
7. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
8. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
9. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
[TBL] [Abstract][Full Text] [Related]
10. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
[TBL] [Abstract][Full Text] [Related]
11. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
Gebauer N; Bernard V; Feller AC; Merz H
Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
Swerdlow SH
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840
[TBL] [Abstract][Full Text] [Related]
13. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature.
Setoodeh R; Schwartz S; Papenhausen P; Zhang L; Sagatys EM; Moscinski LC; Shao H
Int J Clin Exp Pathol; 2013; 6(2):155-67. PubMed ID: 23330001
[TBL] [Abstract][Full Text] [Related]
14. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.
Ott G; Rosenwald A; Campo E
Hematology Am Soc Hematol Educ Program; 2013; 2013():575-83. PubMed ID: 24319234
[TBL] [Abstract][Full Text] [Related]
15. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
Kobayashi T; Tsutsumi Y; Sakamoto N; Nagoshi H; Yamamoto-Sugitani M; Shimura Y; Mizutani S; Matsumoto Y; Nishida K; Horiike S; Asano N; Nakamura S; Kuroda J; Taniwaki M
Jpn J Clin Oncol; 2012 Nov; 42(11):1035-42. PubMed ID: 22984125
[TBL] [Abstract][Full Text] [Related]
16. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
Hummel M; Bentink S; Berger H; Klapper W; Wessendorf S; Barth TF; Bernd HW; Cogliatti SB; Dierlamm J; Feller AC; Hansmann ML; Haralambieva E; Harder L; Hasenclever D; Kühn M; Lenze D; Lichter P; Martin-Subero JI; Möller P; Müller-Hermelink HK; Ott G; Parwaresch RM; Pott C; Rosenwald A; Rosolowski M; Schwaenen C; Stürzenhofecker B; Szczepanowski M; Trautmann H; Wacker HH; Spang R; Loeffler M; Trümper L; Stein H; Siebert R;
N Engl J Med; 2006 Jun; 354(23):2419-30. PubMed ID: 16760442
[TBL] [Abstract][Full Text] [Related]
17. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
[TBL] [Abstract][Full Text] [Related]
18. Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.
Havelange V; Ameye G; Théate I; Callet-Bauchu E; Mugneret F; Michaux L; Dastugue N; Penther D; Barin C; Collonge-Rame MA; Baranger L; Terré C; Nadal N; Lippert E; Laï JL; Cabrol C; Tigaud I; Herens C; Hagemeijer A; Raphael M; Libouton JM; Poirel HA;
Genes Chromosomes Cancer; 2013 Jan; 52(1):81-92. PubMed ID: 23012230
[TBL] [Abstract][Full Text] [Related]
19. Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.
De Falco G; Ambrosio MR; Fuligni F; Onnis A; Bellan C; Rocca BJ; Navari M; Etebari M; Mundo L; Gazaneo S; Facchetti F; Pileri SA; Leoncini L; Piccaluga PP
BMC Cancer; 2015 Oct; 15():668. PubMed ID: 26453442
[TBL] [Abstract][Full Text] [Related]
20. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma.
Smith SM; Anastasi J; Cohen KS; Godley LA
Blood Cells Mol Dis; 2010 Dec; 45(4):317-23. PubMed ID: 20817505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
